Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mesoblast Limited ( (AU:MSB) ) has provided an update.
Mesoblast Limited has appointed James M. O’Brien as its new Chief Financial Officer, a strategic move as the company transitions to a fully integrated commercial organization. O’Brien’s extensive experience in financial management within the life sciences and pharmaceutical industries is expected to bolster Mesoblast’s financial leadership, aiding in the commercialization of its products and potential expansion into new markets.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell therapy technology platform to create therapies that respond to severe inflammation, offering significant reductions in inflammatory processes. Mesoblast’s product Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and the company is expanding its cell therapy offerings to other inflammatory diseases and conditions.
YTD Price Performance: -28.39%
Average Trading Volume: 4,906,603
Technical Sentiment Signal: Buy
Current Market Cap: A$2.85B
Learn more about MSB stock on TipRanks’ Stock Analysis page.